Bridge Biotechnology is a manufacturer of innovative, low carbon disinfection solution -- Esol.

The technology uses less energy and produce less waste than traditional disinfection and purification technologies such as sodium hypochlorite or reverse osmosis and has widespread potential in the fight against coronavirus.

Bridge Biotechnology have developed in house expertise in the production of Esol, an electrochemically activated disinfectant solution that is produced by the electrolysis of salt water in very precisely controlled conditions. The production cell involves an electrolysis process which produces two separate solutions from a double chambered cell separated by a proprietary permeable ion exchange membrane using specialist electronics. The positive chamber produces the Esol solution containing a range of oxidisers giving it a high ORP (oxidation reduction potential). The high ORP environment has been found to be particularly effective against a range of bacteria and virus particles with a rapid kill rate. Esol has been proven to kill E.coli as effectively and at a faster kill rate than 80% alcohol.

The unique, non toxic properties of Esol would allow it to be applied to contaminated areas within healthcare in the form of a fog which would disperse over all surfaces while being safe to inhale and touch for healthcare workers and patients. This project is designed to initially test the efficacy of Esol against SARS-CoV-2 and then extend into developing an innovative fogging system to deliver the disinfectant properties in the most effective way. The fogging system can be developed to control the volume and particle size to be delivered in the optimum way to maximise the efficacy against the virus particles without leaving any traces of moisture.